Literature DB >> 23660937

Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography.

Yusuf Yilmaz1, Rabia Ergelen, Hakan Akin, Nese Imeryuz.   

Abstract

OBJECTIVE: Although ultrasound is a useful technique for detecting hepatic steatosis, it cannot provide a precise determination of hepatic fat content. A novel attenuation parameter named controlled attenuation parameter (CAP) has been developed to process the raw ultrasonic signals acquired by Fibroscan. The aim of this study was to determine the percentage of hepatic steatosis in apparently healthy Turkish individuals using the proposed diagnostic cut-off points for CAP. In addition, we sought to investigate the association of CAP with the traditional risk factors for nonalcoholic fatty liver disease in a screening setting.
MATERIALS AND METHODS: In the present study, 102 Turkish individuals without evidence of fatty liver on ultrasound and normal aminotransferase levels underwent CAP measurements by means of Fibroscan.
RESULTS: The mean (SD), median (minimum-maximum), and 5th and 95th percentile values of CAP values in this cohort of 102 individuals were 206.99 (48.12), 210.5 (100.0-314.0), 113.4 and 280.2 dB/m, respectively. Using the cut-offs of 222, 238, and 283 dB/m for CAP, there were 39 (38.2%), 23 (22.5%), and five (4.9%) individuals out of 102 who had at least 10% steatosis despite normal liver findings on ultrasound. After allowance for potential confounders, CAP was independently associated with BMI (β=0.39, t=3.5, P<0.001) and the number of metabolic syndrome criteria (β=0.24, t=2.1, P<0.05).
CONCLUSION: These results hold promise for early noninvasive detection of hepatic steatosis on the basis of CAP assessment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23660937     DOI: 10.1097/MEG.0b013e3283623a16

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  15 in total

1.  Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea.

Authors:  Young Eun Chon; Kyu Sik Jung; Kwang Joon Kim; Dong Jin Joo; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Seung Up Kim
Journal:  Dig Dis Sci       Date:  2014-08-14       Impact factor: 3.199

2.  Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease.

Authors:  Ivana Mikolasevic; Lidija Orlic; Luka Zaputovic; Sanjin Racki; Zlatko Cubranic; Kata Anic; Bosiljka Devcic; Davor Stimac
Journal:  Wien Klin Wochenschr       Date:  2015-04-09       Impact factor: 1.704

3.  Controlled Attenuation Parameter as a Noninvasive Method to Detect and Quantify Hepatic Steatosis in Chronic Liver Disease: What Is the Clinical Relevance?

Authors:  Mariana Verdelho Machado
Journal:  GE Port J Gastroenterol       Date:  2017-07-04

4.  Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study.

Authors:  Meryem Demir; Oğuzhan Deyneli; Yusuf Yılmaz
Journal:  Turk J Gastroenterol       Date:  2019-03       Impact factor: 1.852

Review 5.  Non-alcoholic fatty liver disease: what the clinician needs to know.

Authors:  Mariana Verdelho Machado; Helena Cortez-Pinto
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 6.  Non-invasive diagnosis of hepatic steatosis.

Authors:  Christiane Stern; Laurent Castera
Journal:  Hepatol Int       Date:  2016-10-25       Impact factor: 6.047

Review 7.  Non-alcoholic fatty liver disease: A growing public health problem in Turkey.

Authors:  Eda Kaya; Yusuf Yılmaz
Journal:  Turk J Gastroenterol       Date:  2019-10       Impact factor: 1.852

8.  PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes.

Authors:  Rosellina Margherita Mancina; Rocco Spagnuolo; Marta Milano; Simona Brogneri; Attilio Morrone; Cristina Cosco; Veronica Lazzaro; Cristina Russo; Yvelise Ferro; Piero Pingitore; Arturo Pujia; Tiziana Montalcini; Patrizia Doldo; Pietro Garieri; Luca Piodi; Flavio Caprioli; Luca Valenti; Stefano Romeo
Journal:  Inflamm Bowel Dis       Date:  2016-01       Impact factor: 5.325

9.  Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic.

Authors:  Ayşegül Avcu; Eda Kaya; Yusuf Yilmaz
Journal:  Turk J Gastroenterol       Date:  2021-05       Impact factor: 1.852

Review 10.  A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence.

Authors:  Jonathan L Temple; Paul Cordero; Jiawei Li; Vi Nguyen; Jude A Oben
Journal:  Int J Mol Sci       Date:  2016-06-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.